Current research on methamphetamine-induced neurotoxicity: Animal models of monoamine disruption

Journal of Pharmacological Sciences

Volumn 92, Issue 3, 2003, Pages 178-195

  Kita, Taizo ^a,b   Wagner, George C ^c   Nakashima, Toshikatsu ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b DAIICHI UNIVERSITY OF PHARMACY   (Japan)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

Apoptosis; Dopamine; Free radical; Methamphetamine; Neurotoxicity

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; AMPHETAMINE; AMPHETAMINE DERIVATIVE; BENSERAZIDE; CASPASE 3; CATHINONE; CHLORAMPHETAMINE; CHLORPROMAZINE; DIZOCILPINE; DOPAMINE; DOPAMINE TRANSPORTER; FENFLURAMINE; FLUOXETINE; FREE RADICAL; GLUTAMIC ACID; LEVODOPA; METHAMPHETAMINE; METHYLPHENIDATE; MONOAMINE; MONOAMINE TRANSPORTER 2; N METHYLASPARTIC ACID; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROTEIN BCL 2; PROTEIN C FOS; PROTEIN P53; REACTIVE OXYGEN METABOLITE; RESERPINE; SEROTONIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGE; ANIMAL MODEL; ANOREXIA; APOPTOSIS; AUTISM; AUTOMUTILATION; AUTOOXIDATION; BEHAVIOR DISORDER; CATECHOLAMINE DEPLETION; CORPUS STRIATUM; CYTOPLASM; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG ABUSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG MEGADOSE; DRUG POTENTIATION; ENZYME ACTIVITY; EXCITABILITY; GENETIC MANIPULATION; HUMAN; HYPERACTIVITY; HYPERHIDROSIS; HYPERTENSION; HYPERTHERMIA; INSOMNIA; KNOCKOUT MOUSE; LETHALITY; LOW DRUG DOSE; NERVE DEGENERATION; NERVE INJURY; NEUROCHEMISTRY; NEUROTOXICITY; NICK END LABELING; NONHUMAN; OXIDATIVE STRESS; PARANOID SCHIZOPHRENIA; PARKINSON DISEASE; PROTEIN EXPRESSION; REVIEW; SEROTONINERGIC SYSTEM; SEX DIFFERENCE; SIDE EFFECT; SUPERSENSITIVITY; SYNAPSE VESICLE; TACHYCARDIA; TACHYPNEA; TREMOR;

EID: 0041563924     PISSN: 13478613     EISSN: None     Source Type: Journal    
DOI: 10.1254/jphs.92.178     Document Type: Review

References (161)

1. Cadet JL, Brannock C. Free radicals and the pathobiology of brain dopamine systems. Neurochem Int. 1998;32:117-131.
2. Frost DO, Cadet JL. Effects of METH-induced neurotoxicity on the development of neural circuitry: A hypothesis. Brain Res Brain Res Rev. 2000;34:103-118.
3. Kita T, Nakashima T. A recent trend in METH-induced neurotoxicity. Nihon Shinkei Seishin Yakurigaku Zasshi. 2002;22:35-47. article in Japanese.
4. Gerlach M, Reiderer P. Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man. J Neural Trans. 1996;103:987-1041.
5. Asanuma M, Hayashi T, Ordonez SV, Ogawa N, Cadet JL. Direct interactions of METH with the nucleus. Mol Brain Res. 2000;80:237-243.
6. Weiss B, Laties VG. Drug effects on the temporal patterning of behavior. Fed Proc. 1964;23:801-807.
7. Schuster CR, Dockens WS, Woods JH. Behavioral variables affecting the development of amphetamine tolerance. Psychopharmacology (Berl). 1966;9:170-182.
8. Segal DS, Mandell AJ. Long-term administration of d-amphetamine: Progressive augmentation of motor activity and stereotypy. Pharmacol Biochem Behav. 1974;2:249-255.
9. Campbell JC, Seiden LS. Performance influence on the development of tolerance to amphetamine. Pharmacol Biochem Behav. 1973;1:703-708.
10. Kalant OJ. The Amphetamines: Toxicity and Addiction. Toronto: Univ of Toronto Press; 1973.
11. Cook JD, Schanberg SM. Effect of METH on NE metabolism in various regions of brain. J Pharmacol Exp Ther. 1975;195:87-93.
12. 3H-NE in slices of rat neostriatum and cerebral cortex. J Pharmacol Exp Ther. 1977;194:47-56.
13. Ross SB. Antagonism by methylphenidate of the stereotyped behaviour produced by (+) amphetamine in reserpinized rats. J Pharm Pharmacol. 1978:30:253-254.
14. Lewander T. On the presence of p-hydroxynorephedrine in the rat brain and heart in relation to changes in catecholamine levels after administration of amphetamine. Acta Pharmacol Toxicol. 1971;29:33-48.
15. Breese GR, Cooper BR, Mueller RA. Evidence for involvement of 5-hydroxytryptamine in the actions of amphetamine. Br J Pharmacol. 1974;52:307-314.
16. Kuczenski R. Effects of para-chlorophenylalanine on amphetamine- and haloperidol-induced changes in striatal dopamine turnover. Brain Res. 1978;164:217-225.
17. Howlett DR, Nahorski SR. Acute and chronic treatments modulate striatal dopamine binding sites. Brain Res. 1979;161:173-178.
18. Reiseine TD, U'Prichard DC, Wiech NL, Ursillo RC, Yamamura HI. Effects of combined administration of amphetamine and iprindole on brain adrenergic receptors. Brain Res. 1980;188:587-592.
19. Bailey RC, Jackson DM. A pharmacological study of changes in the central nervous system receptor responsiveness after long-term dexamphetamine and apomorphine administration. Psychopharmacology (Berl). 1978;56:317-326.
20. Klawans HL, Margolin DI. Amphetamine-induced dopaminergic hypersensitivity in guinea pigs. Arch Gen Psychiatry. 1975;32:725-732.
21. Jenner P, Pycock C, Marsden CD. The effect of chronic administration and withdrawal of amphetamine on cerebral dopamine receptor sensitivity. Psychopharmacology (Berl). 1978;58:131-136.
22. Fischman MW, Schuster CR. Tolerance development to chronic METH intoxication in the rhesus monkey. Pharmacol Biochem Behav. 1974;2:503-508.
23. Seiden LS, Fischman MW, Schuster CR. Long-term METH induced changes in brain catecholamines in tolerant rhesus monkeys. Drug Alcohol Depend. 1975/1976;1:215-219.
24. 14 METH in man, the guinea pig and the rat. Biochem J. 1972;129:11-22.
25. Wagner GC, Seiden LS, Schuster CR. METH-induced changes in brain catecholamines in rats and guinea pigs. Drug Alcohol Depend. 1979;4:435-438.
26. Wagner GC, Ricaurte GA, Seiden LS, Schuster CR, Miller RJ, Westley J. Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of METH. Brain Res. 1980;181:151-160.
27. Bittner SE, Wagner GC, Aigner TG, Seiden LS. Effects of a high-dose treatment of METH on caudate dopamine and anorexia in rats. Pharmacol Biochem Behav. 1981;14:481-486.
28. Kramer JC, Fischman VS, Littlefield DC. Amphetamine abuse. JAMA. 1967;201:305-310.
29. Melega WP, Raleigh MJ, Stout DB, Lacan G, Huang S-C, Phelps ME. Recovery of striatal dopamine function after acute amphetamine-and METH-induced neurotoxicity in the vervet monkey. Brain Res 1997;766:113-120.
30. Harvey DC, Lacan G, Tanious SP, Melega WP. Recovery from METH induced long-term nigrostriatal dopaminergic deficits without substantia nigra cell loss. Brain Res. 2000;871:259-270.
31. Wilson JM, Kalasinsky KS, Levey AI, et al. Striatal dopamine nerve terminal markers in human, chronic METH users. Nature Med. 1996;2:699-703.
32. 11C]WIN-35,428. J Neurosci. 1998;18:8417-8422.
33. Volkow ND, Chang L, Wang GJ, et al. Association of dopamine transporter reduction with psychomotor impairment in METH abusers. Am J Psychiatry. 2001;158:377-382.
34. Gibb JW, Kogan FJ. Influence of dopamine synthesis on METH-induced changes in striatal and adrenal tyrosine hydroxylase activity. Naunyn Schmiedebergs Arch Pharmacol. 1979;310:185-187.
35. Wagner GC, Ricaurte GA, Johanson CE, Schuster CR, Seiden LS. Amphetamine induces depletion of dopamine and loss of dopamine uptake sites in caudate. Neurology. 1980;30:547-550.
36. Steranka LR, Sanders-Bush E. Long-term effects of continuous exposure to amphetamine on brain dopamine concentration and synaptosomal uptake in mice. Eur J Pharmacol. 1980;65:439-443.
37. Fuller RW, Hemrick-Luecke S. Long-lasting depletion of striatal dopamine by a single injection of amphetamine in iprindole-treated rats. Science. 1980;209:305-307.
38. Trulson ME, Jacobs BL. Chronic amphetamine administration to cats: Behavioral and neurochemical evidence for decreased central serotonergic function. J Pharmacol Exp Ther. 1979;211:375-384.
39. Trulson ME, Jacobs BL. Chronic amphetamine administration decreases brain tryptophan hydroxylase activity in cats. Life Sci. 1980;26:329-335.
40. Ricaurte GA, Schuster CR, Seiden LS. Long-term effects of repeated methylamphetamine administration on dopamine and 5-HT neurons in the rat brain: A regional study. Brain Res 1980;193:153-163.
41. Friedman SD, Castaneda E, Hodge GK. Long-term monoamine depletion, differential recovery, and subtle behavioral impairment following METH-induced neurotoxity. Pharmacol Biochem Behav. 1998;61:35-55.
42. Nelson MM, Forfar JO. Association between drugs administered during pregnancy and congenital abnormalities of the fetus. Br Med J. 1971;1:523-527.
43. Nora JJ, McNamara DG, Fraser FC. Dexamphetamine sulphate and human malformation. Lancet. 1967;1:570-571.
44. Nasello AG, Ramirez OA. Brain catecholamine metabolism in offspring of amphetamine treated rats. Pharmacol Biochem Behav. 1978;9:17-20.
45. Bell RW, Drucker RR, Woodruff AB. The effects of prenatal injections of adrenalin chloride and d-amphetamine sulfate on subsequent emotionality and ulcer proneness of offspring. Psychon Sci. 1965;2:269-270.
46. Clark CV, Gorman D, Vernodakis A. Effects of prenatal administration of psychotropic drugs on behavior ofd developing rats. Dev Psychobiol. 1970;2:225-235.
47. Tonge S. Permanent alterations in catecholamine concentrations in discrete areas of brain in the offspring of rats treated with methylamphetamine and chlorpromazine. Br J Pharmacol. 1973;47:425-427.
48. Middaugh LD, Blackwell LA, Santos CA, Zemp JW. Effects of d-amphetamine sulfate given to pregnant mice on activity and on catecholamines in the brains of offspring. Dev Psychobiol. 1974;7:429-438.
49. Hitzemann BA, Hitzemann RJ, Brase DA, Loh HH. Influence of prenatal d-amphetamine administration on development and behavior of rats. Life Sci. 1976;18:605-612.
50. Wagner GC, Schuster CR, Seiden LS. Neurochemical consequences following administration of CNS stimulants to the neonatal rat. Pharmacol Biochem Behav. 1981;14:117-119.
51. Lal H, Sourkes TL. Ontogeny of stereotyped behavior induced by apomorphine and amphetamine in the rat. Arch Int Pharmacodyn Ther. 1973;202:171-182.
52. Lytle LD, Keil FC. Brain and peripheral monoamines: Possible role in the ontogenesis of normal and drug-induced responses in the immature mammal. In: Fuxe K, Olsen L, Zotterman Y, editors. Dynamics of Degeneration and Growth. New York: Pergamon; 1974. p. 575-592.
53. Wagner GC, Lucot JB, Schuster CR, Seiden LS. The ontogeny of aggregation enhanced toxicity. Psychopharmacology (Berl). 1981;75:92-93.
54. Levine MS, Hull CD, Garcia-Rill E, Erinoff L, Bchwald NA, Heller A. Long-lasting decreases in spontaneous firing of caudate neurons induced by amphetamine in cats. Brain Res. 1980;194:263-268.
55. Vorhees CV, Pu C. Ontogeny of METH-induced neurotoxicity in the rat model. NIDA Res Monogr. 1995;158:149-171.
56. Wallace TL, Gudelsky GA, Vorhees CV. Neurotoxic regimen of METH produces evidence of behavioral sensitization in the rat. Synapse. 2001;39:1-7.
57. Wagner GC, Walsh SW. Evaluation of the effects of inhibition of monoamine oxidase and senescence on METH induced neuronal damage. Int J Dev Neurosci. 1991;9:171-174.
58. Mahy N, Andres N, Andrade C, Saura J. Age-related changes of MAO-A and -B distribution in human and mouse brain. Neurobiology. 2000;8:47-54.
59. Wagner GC, Tekirian TL, Cheo CT. Sexual differences in sensitivity to METH toxicity. J Neural Transm. 1993;93:67-70.
60. Yu L, Liao P-C. Sexual differences and estrous cycle in METH-induced dopamine and 5-HT depletions in the striatum of mice. J Neural Transm. 2000;107:419-427.
61. Yu L, Wagner GC. Influence of gonadal hormones on sexual differences in sensitivity to METH-induced neurotoxicity. J Neural Transm. 1994;8:215-221.
62. Fukumura M, Cappon GD, Broening HW, Vorhees CV. METH-induced dopamine and 5-HT reductions in neostriatum are not gender specific in rats with comparable hyperthermic effects. Neurotoxicol Teratol. 1998;20:441-448.
63. Kogan FJ, Nichols WK, Gibb JW. Influence of METH on nigral and striatal tyrosine hydroxylase activity and on striatal dopamine levels. Eur J Pharmacol. 1976;36:363-371.
64. Ellison G, Eison MS, Huberman HS, Daniel F. Long-term changes in dopaminergic innervation of caudate nucleus after continuous amphetamine administration. Science. 1978;201:276-278.
65. Hotchkiss AJ, Gibb JW. Long-term effects of multiple doses of METH on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain. J Pharmacol Exp Ther. 1980;214:257-262.
66. Bower F, Frame LT, Clausing P, et al. Long-term effects of amphetamine neurotoxicity on tyrosine hydroxylase mRNA and protein in aged rats. J Pharmacol Exp Ther. 1998;286:1074-1085.
67. Hotchkiss AJ, Morgan ME, Gibb JW. The long-term effects of multiple doses of METH on neostriatal tryptophan hydroxylase, tyrosine hydroxylase, choline acetyltransferase and glutamate decarboxylase activities. Life Sci. 1979;25:1373-1378.
68. Fukumura M, Cappon GD, Pu C, Broening HW, Vorhees CV. A single dose model of METH-induced neurotoxicity in rats: Effects on neostriatal monoamines and glial fibrillary acidic protein. Brain Res. 1998;806:1-7.
69. Ricaurte GA, Schuster CR, Seiden LS. Increased dopamine metabolism in the rat neostriatum after toxic doses of d-methyl-amphetamine. Neuropharmacology. 1983;22:1383-1388.
70. Cass WA, Manning MW. Recovery of presynaptic dopaminergic functioning in rats treated with neurotoxic doses of METH. J Neurosci. 1999;19:7653-7660.
71. 2 dopamine receptors as evidenced by autoradiography comparison with tyrosine hydroxylase activity. Neuroscience. 1987;23:253-261.
72. Fields JZ, Wichlinski L, Drucker GE, Engh K, Gordon JH. Long-lasting dopamine receptor up-regulation in amphetamine-treated rats following amphetamine neurotoxicity. Pharmacol Biochem Behav. 1991;40:881-886.
73. Morgan ME, Gibb JW. Short-term and long-term effects of METH on biogenic amine metabolism in extra-striatal dopaminergic nucleic. Neuropharmacology. 1980;19:989-995.
74. Marshall JF, Navarrete RJ. Contrasting tissue factors predict heterogenous striatal dopamine neurotoxicity after MPTP or METH treatment. Brain Res. 1990;534:348-351.
75. Eisch A, Gaffney M, Weihmuller FB, O'Dell SJ, Marshall JF. Striatal subregions are differentially vulnerable to the neurotoxic effects of METH. Brain Res. 1992;598:321-326.
76. Miyakawa T, Sumiyoshi S, Deshimaru M, Murayama E, Tatetsu E. Electron microscopic studies concerning the structural mechanism of the development of mental disturbance in experimental chronic METH poisoning. Acta Neuropathol. 1969;14:215-225.
77. Lorez H. Fluorescence histochemistry indicates damage of striatal dopamine nerve terminals in rats after multiple doses of METH. Life Sci. 1981;28:911-916.
78. Jonsson G, Nwanze E. Selective (+)-amphetamine neurotoxicity on striatal dopamine nerve terminals in the mouse. Br J Pharmacol. 1982;77:335-345.
79. Ricaurte GA, Guillery RW, Seiden LS, Schuster CR, Moore RY. Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in rat brain. Brain Res. 1982;235:92-103.
80. Hess A, Desiderio C, McAuliffe WG. Acute neuropathological changes in the caudate nucleus caused by MPTP and METH: Immunohistochemical studies. J Neurocytol. 1990;19:338-342.
81. Eisch A, Schmued L, Marshall JF. Characterizing cortical neuron injury with fluoro-jade labeling after a neurotoxic regimen of METH. Synapse. 1998;30:329-333.
82. Schmued LC, Bowyer JF. METH exposure can produce neuronal degeneration in mouse hippocampal remnants. Brain Res. 1997;759:135-140.
83. Sonsalla PK, Jochnowitz ND, Zeevalk GD, Oostveen JA, Hall ED. Treatment of mice with METH produces cell loss in the substantia nigra. Brain Res. 1996;738:172-175.
84. Marek GJ, Vosmer G, Seiden LS. Dopamine uptake inhibitors block long-term neurotoxic effects of METH upon dopamine neurons. Brain Res. 1990;513:274-279.
85. Wagner GC, Preston KL, Ricaurte GA, Schuster CR, Seiden LS. Neurochemical similarities of cathinone and amphetamine. Drug Alcohol Depend. 1982;9:279-284.
86. Ryan LJ, Martone ME, Linder JC, Groves PM. Cocaine, in contrast to d-amphetamine, does not cause axonal terminal degeneration in neostriatum and agranular frontal cortex of Long-Evans rats. Life Sci. 1988;43:1403-1409.
87. Wagner GC, Gardner J, Tsigas DJ, Masters DB. Tolerance following the repeated administration of high doses of phencyclidine: No relation to central catecholamine depletion. Drug Alcohol Depend. 1984;13:225-234.
88. Wagner GC, Jarvis MF. Evaluation of the pharmacological similarities between phenylpropanolamine and amphetamine: Effects on schedule-controlled behavior. Synapse. 1990;6:101-105.
89. Harvey JA, McMaster SE, Fuller RW. Comparison between the neurotoxic and 5-HT-depleting effects of various halogenated derivatives of amphetamine in the rat. J Pharmacol Exp Ther. 1977;202:581-589.
90. Ricaurte GA, Bryan G, Strauss L, Seiden LS, Schuster CR. Hallucinogenic amphetamine selectivity destroys brain serotonin nerve terminals. Science. 1985;229:986-988.
91. Axt KJ, Commins DL, Vosmer G, Seiden LS. α-methyl-p-tyrosine pretreatment partially prevents METH-induced endogenous neurotoxicn formation. Brain Res. 1990;515:269-276.
92. Wagner GC, Lucot JB, Schuster CR, Seiden LS. Alpha-methyl-tyrosine attenuates and reserpine increases METH-induced neuronal changes. Brain Res. 1983:270;285-288.
93. Schmidt CJ. L-Dopa potentiates the neurotoxicity of some amphetamine analogues. Ann NY Acad Sci. 1992;648:343-344.
94. Seiden LS, Vosmer G. Formation of 6-hydroxydopamine in caudate nucleus of the rat brain after a single large dose of methylamphetamine. Pharmacol Biochem Behav. 1984;21:29-31.
95. Marek GJ, Vosmer G, Seiden LS. Dopamine uptake inhibitors block long-term neurotoxic effects of METH upon dopaminergic neurons. Brain Res. 1990;513:274-279.
96. Gibb JW, Johnson M, Hanson GR. Neurochemical basis of neurotoxicity. Neurotoxicology. 1990;11:317-321.
97. Kita T, Wagner GC, Philbert MA, King LA, Lowndes HE. Effects of pargyline and pyrogallol on the METH-induced dopamine depletion. Mol Chem Neuropathol. 1995;24:31-41.
98. Wagner GC, Carelli RM, Jarvis MF. Ascorbic acid reduces the dopamine depletion induced by METH and the 1-methyl-4-phenyl pyridinium ion. Neuropharmacology. 1986;25:559-561.
99. De Vito MJ, Wagner GC. METH-induced neuronal damage: A possible role for free radicals. Neuropharmacology. 1989;28:1145-1150.
100. Cadet JL, Sheng P, Ali S, Rothman R, Carlson E, Esptein C. Attenuation of METH-induced neurotoxicity in copper/zinc superoxide dismutase transgenic mice. J Neurochem. 1994;62:380-383.
101. Hirata H, Ladenheim B, Carlson E, Epstein C, Cadet JL. Auto-radiographic evidence for METH-induced striatal dopaminergic loss in mouse brain: Attenuation of CuZn-superoxide dismutase transgenic mice. Brain Res. 1996;714:95-103.
102. Giovanni A, Liang LP, Hastings TG, Zigmond MJ. Estimating hydroxyl radical content in rat brain using systemic and intraventricular salicylate: Impact of METH. J Neurochem. 1995;64:1819-1825.
103. Kita T, Takahashi M, Kubo K, Wagner GC, Nakashima T. Hydroxyl radical formation following METH administration to rats. Pharmacol Toxicol. 1999;85:133-137.
104. Cubells JF, Rayport S, Rajendran G, Sulzer D. METH neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J Neurosci. 1994;14:2260-2271.
105. Fumagalli F, Gainetdinov RR, Wang YM, Valenzano KJ, Miller GW, Caron MG. Increased METH neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J Neurosci. 1999;19:2424-2431.
106. Carlsson M, Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia-Implications for schizophrenia and Parkinson's disease. Trends Neurosci. 1990;13:272-276.
107. Sonsalla PK, Nicklas WJ, Heikkila RE. Role for excitatory amino acids in METH-induced nigrostriatal dopaminergic toxicity. Science. 1989;243:398-400.
108. Nash JF, Yamamoto BK. METH neurotoxicity and striatal glutamate release: Comparison to 3,4-methylenedioxy-METH. Brain Res. 1992;581:237-243.
109. Abekawa T, Ohmori T, Koyama T. Effects of repeated administration of a high dose of METH on dopamine and glutamate release in rat striatum and nucleus accumbens. Brain Res. 1994;643:276-281.
110. Stephans SE, Yamamoto BK. METH-induced neurotoxicity: Roles for glutamate and dopamine efflux. Synapse. 1994;17:203-209.
111. Itzhak Y, Gandia C, Huang PL, Ali SF. Resistance of neuronal nitric oxide synthase-deficient mice to METH-induced dopaminergic neurotoxicity. J Pharmacol Exp Ther. 1998;284:1040-1047.
112. Garthwaite J. Glutamate, nitric oxide, and cell-cell signaling in the nervous system. Trends Neurosci. 1991;14:60-67.
113. Snyder SH. Nitric oxide: First in a new class of neurotrasmitters. Science. 1992;257:494-496.
114. Beckman JS, Beckman TW, Chen J, Marshall PM, Freeman BA. Apparent hydroxy radical production by peroxynitrite; Implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA. 1990;87:1621-1624.
115. Pisani A, Calabresi P, Centonze D, Bernardi G. Enhancement of NMDA responses by group-1 metabotropic glutamate receptor activation in striatal neurones. Br J Pharmacol. 1997;120:1007-1014.
116. Salt TE, Binns KE. Contributions of mGlu1 and mGku5 receptors to interactions with N-methyl-D-aspartate receptor-mediated responses and nociceptive sensory responses of rat thalamic neurons. Neuroscience. 2000;100:375-380.
117. Bruno V, Ksiazek I, Battaglia G, et al. Selective blockage of metabotropic glutamate receptor subtype 5 is neuroprotective. Neuropharmacology. 2000;39:2223-2230.
118. Battaglia G, Fornai F, Busceti CL, et al. Selective blockade of mGlu5 metabotropic glutamate receptors is protective against methamphetamine neurotoxicity. J Neurosci. 2002;22:2135-2142.
119. Shimazoe T, Doi Y, Arai I, Yoshimatsu A, Fukumoto T, Watanabe S. Both metabotropic glutamate I and II receptors mediate augmentation of dopamine release from the striatum in METH-sesitized rats. Jpn J Pharmacol. 2002;88:85-88.
120. Iwasa M, Maeno Y, Inoue H, Koyama H, Matoba R. Induction of apoptotic cell death in rat thymus and spleen after a bolus injection of METH. Int J Legal Med. 1996;109:23-28.
121. Cadet JL, Ordonez, SV, Ordonez JV. METH induces apoptosis in immortalized neural cells: Protection by the proto-oncogene, bcl-2. Synapse. 1997;25:176-184.
122. Stumm G, Schlegel J, Schafer T, et al. Amphetamines induce apoptosis and regulation of bcl-x splice variants in neocortical neurons. FASEB J. 1999;13:1065-1072.
123. Hirata H, Cadet JL. METH-induced 5-HT neurotoxicity is attenuated in p53-knockout mice. Brain Res. 1997;768:345-348.
124. Deng X, Jayanthi S, Ladenheim B, Krasnova IN, Cadet JL. Mice with partial deficiency of c-Jun show attenuation of METH-induced neuronal apoptosis. Mol Pharmacol. 2002;62:993-1000.
125. Lunchins DJ. Self-injurious behavior: Introduction. Prog Neuro-psychopharmacol Biol Psychiatry. 1990;14:S63-S64.
126. Anderson LT, Ernst M. Self-injury in Lesch-Nyhan disease. J Autism Dev Dis. 1994;24:67-81.
127. Lesch M, Nyhan WL. A familial disorder of uric acid metabolism and central nervous function. Am J Med. 1964;36:561-570.
128. Oliver C, Murphy GH, Cobett JA. SIB in people with mental handicap: A total population study. J Ment Def Res. 1987;31:147-162.
129. Sandyk R. Self-mutilation in Tourette's syndrome. J Child Neurol. 1988;3:147-148.
130. Khouzam HR, Donnelly NJ. Remission of self-mutilation in a patient borderline personality during risperidone therapy. J Nervous Ment Dis. 1997;185:348-349.
131. Breese G, Baumeister A, McCown T, et al. Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: Relevance to neurological symptoms in clinical syndromes with reduced brain dopamine. J Pharmacol Exp Ther. 1984;231:343-354.
132. Stodgell CJ, Loupe PS, Schroeder SR, Tessel RE. Cross-sensitizarion between footshock stress and apomorphine on self-injurious behavior in rat model of Lesch Nyhan syndrome. Brain Res. 199;783:10-18.
133. Jinnah HA, Langlais PJ, Friedmann T. Functional analysis of brain dopamine systems in a genetic mouse model of Lesch-Nyhan syndrome. J Pharmacol Exp Ther. 1992;263:596-607.
134. Saito Y, Takashima S. Neurotransmitter changes in the pathophysiology of Lesch-Nyhan syndrome. Brain Dev. 2000;22 Suppl 1:S122-S131.
135. Kita T, Paku S, Takahashi M, Kubo K, Wagner GC, Nakashima T. METH-induced neurotoxicity in BALB/c, DBA/2N and C57BL/6N mice. Neuropharmacology. 1998;37:1177-1184.
136. Kita T, Matsunari Y, Saraya T, et al. METH-induced striatal dopamine release, behavior changes and neurotoxicity in BALB/c mice. Int J Dev Neurosci. 2000;18:521-530.
137. Kita T, Shimada K, Mastunari Y, Wagner GC, Kubo K, Nakashima T. METH-induced striatal dopamine neurotoxicity and cyclooxygenase-2 protein expression in BALB/c mice. Neuropharmacology. 2000;39:399-406.
138. Dickson PR, Lang CG, Hinton SC, Kelly AE. Oral stereotypy induced by amphetamine microinjection into striatum; An anatomical mapping study. Neuroscience. 1994;61:81-91.
139. Mueller K, Saboda S, Palmour R, Nyhan WL. Self-injurious behavior produced in rats by daily caffeine and continuous amphetamine. Pharmacol Biochem Behav. 1982;17:613-617.
140. Moy SS, Criswell HE, Breese GR. Differential effects of bilateral dopamine depletion in neonatal and adult rats. Neurosci Biobehav Rev. 1997;21:425-435.
141. Towle AC, Criswell HE, Maynard EH, et al. Serotonergic innervation of the rat caudate following a neonatal 6-hydroxy-dopamine lesion: An anatomical, biochemical and pharmacological study. Pharmacol Biochem Behav. 1989;34:367-374.
142. Biggs CS, Starr CS. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-dopa-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum. Synapse. 1999;34:36-46.
143. Myers CS, Witten M, Yu Y, Wagner GC. L-Dopa exacerbates amphetamine-induced dopamine depletion. Mol Chem Neuropath. 1998;33:81-97.
144. Bowyer JF, Tank AW, Newport GD, Slikker W Jr, Ali SF, Holson RR. The influence of environmental temperature on the transient effects of METH on dopamine levels and dopamine release in rat striatum. J Pharmacol Exp Ther. 1992;260:817-824.
145. Bowyer JF, Gough B, Slikker W Jr, Lipe GW, Newport GD, Holson RR. Effects of a cold environment or age on METH-induced dopamine release in the caudate putamen of female rats. Pharmacol Biochem Behav. 1993;44:87-98.
146. Ali SF, Newport GD, Holson RR, Slikker W Jr, Bowyer JF. Low environmental temperatures or pharmacologic agents that produce hypothermia decrease METH neurotoxicity in mice. Brain Res. 1994;658:33-38.
147. Bowyer JF, Davies DL, Schmued L, et al. Further studies of the role of hyperthermia in METH neurotoxicity. J Pharmacol Exp Ther. 1994;268:1571-1580.
148. Yamaguchi T, Kuraishi Y, Minami M, Nakai S, Hirai Y, Satoh M. METH-induced expression of interleukin-1 beta mRNA in the rat hypothalamus. Neurosci Lett. 1991;128:90-92.
149. Guilarte TR. Is METH abuse a risk factor in Parkinsonism? Neurotoxicology. 2001;22:725-731.
150. Fischman MW, Schuster CR. Long-term behavioral changes in the rhesus monkey after multiple daily doses of d-methyl-amphetamine. J Pharmacol Exp Ther. 1977;201:593-605.
151. Richards JB, Baggott MJ, Sabol KS, Seiden LS. A high-dose METH regimen results in long-lasting deficits on performance of a reaction time task. Brain Res. 1993;627:254-260.
152. Seiden LS, Carlsson A. Temporary and partial antagonism by L-dopa of reserpine-induced suppression of a conditioned avoidance response. Psychopharmacologia (Berl). 1963;4:418-423.
153. Seiden LS, Carlsson A. Brain and heart catecholamine levels after L-dopa administration in reserpine-treated mice: Correlation with a conditioned avoidance response. Psychopharmacologia (Berl). 1964;5:178-181.
154. Walsh SL, Wagner GC. Motor impairments following METH-induced neurotoxicity in the rat. J Pharmacol Exp Ther. 1992;263:617-626.
155. Sabol KE, Roach JT, Broom SL, Ferreira C, Preau MM. Long-term effects of a high-dose methamphetamine regimen on subsequent methamphetamine-induced dopamine release in vivo. Brain Res. 2001;892:122-129.
156. Deng X, Wang Y, Chou J, Cadet JL. Methamphetamine causes widespread apoptosis in the mouse brain: Evidence from using an improved TUNEL histochemical method. Brain Res Mol Brain Res. 2001;93:64-69.
157. Jayanthi S, Deng X, Bordelon M, McCoy MT, Cadet JL. Methamphetamine causes differential regulation of pro-death and anti-death Bcl-2 genes in the mouse neocortex. FASEB J. 2001;15:1745-1752.
158. Imam SZ, Newport GD, Itzhak Y, et al. Peroxynitrite plays a role in methamphetamine-induced dopaminergic neurotoxicity: Evidence from mice lacking neuronal nitric oxide synthase gene or overexpressing copper-zinc superoxide dismutase. J Neurochem. 2001;76:745-749.
159. Thiriet N, Jayanthi S, McCoy M, Ladenheim B, Cadet JL. Methamphetamine increases expression of the apoptotic c-myc and L-myc genes in the mouse brain. Mol Brain Res. 2001;90:202-204.
160. Deng X, Cadet JL. Methamphetamine-induced apoptosis in attenuated in the striata of copper-zinc superoxide dismutase transgenic mice. Mol Brain Res. 2000;83:121-124.
161. Deng X, Ladenheim B, Tsao LI, Cadet JL. Null mutation of c-fos causes exacerbation of methamphetamine-induced neurotoxicity. J Neurosci. 1999;19:10107-10115.